For women specifically concerned about PCOS-related hair issues, the relationship between GLP-1 medications and hair loss is important to understand
A consultation is required to determine eligibility
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
Thalia Segal
Short surveys with obesity-clinic dietitians validated price sensitivity and substitution assumptions drawn from secondary data
Current therapeutic options for mild TAO include observation, patient education, lifestyle changes (i.e., smoking cessation, salt restriction, sun protection) and ocular surface lubrication